We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $48.05 in the latest trading session, marking a +0.47% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%.
The the stock of company has risen by 0.18% in the past month, leading the Medical sector's loss of 3.35% and undershooting the S&P 500's gain of 4.31%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. The company is expected to report EPS of -$1.45, down 2.84% from the prior-year quarter.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.58 per share and revenue of $64.2 million. These results would represent year-over-year changes of -187.63% and -82.7%, respectively.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
CRISPR Therapeutics AG (CRSP - Free Report) closed at $48.05 in the latest trading session, marking a +0.47% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%.
The the stock of company has risen by 0.18% in the past month, leading the Medical sector's loss of 3.35% and undershooting the S&P 500's gain of 4.31%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. The company is expected to report EPS of -$1.45, down 2.84% from the prior-year quarter.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.58 per share and revenue of $64.2 million. These results would represent year-over-year changes of -187.63% and -82.7%, respectively.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.